Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Nov;141(5):1665-72.e1-9.
doi: 10.1053/j.gastro.2011.07.051. Epub 2011 Aug 16.

Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury

Affiliations

Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury

Timothy J Davern et al. Gastroenterology. 2011 Nov.

Abstract

Background & aims: The diagnosis of drug-induced liver injury relies on exclusion of other causes, including viral hepatitis A, B, and C. Hepatitis E virus (HEV) infection has been proposed as another cause of suspected drug-induced liver disease. We assessed the frequency of HEV infection among patients with drug-induced liver injury in the United States.

Methods: The Drug-Induced Liver Injury Network (DILIN) is a prospective study of patients with suspected drug-induced liver injury; clinical information and biological samples are collected to investigate pathogenesis and disease progression. We analyzed serum samples, collected from patients enrolled in DILIN, for immunoglobulin (Ig) G and IgM against HEV; selected samples were tested for HEV RNA.

Results: Among 318 patients with suspected drug-induced liver injury, 50 (16%) tested positive for anti-HEV IgG and 9 (3%) for anti-HEV IgM. The samples that contained anti-HEV IgM (collected 2 to 24 weeks after onset of symptoms) included 4 that tested positive for HEV RNA genotype 3. Samples from the 6-month follow-up visit were available from 4 patients; they were negative for anti-HEV IgM, but levels of anti-HEV IgG increased with time. Patients who had anti-HEV IgM were mostly older men (89%; mean age, 67 years), and 2 were human immunodeficiency virus positive. Clinical reassessment of the 9 patients with anti-HEV IgM indicated that acute hepatitis E was the most likely diagnosis for 7 and might be the primary diagnosis for 2.

Conclusions: HEV infection contributes to a small but important proportion of cases of acute liver injury that are suspected to be drug induced. Serologic testing for HEV infection should be performed, particularly if clinical features are compatible with acute viral hepatitis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: Dr. Chalasani has received consulting fees regarding drug-induced liver injury in the past 12 months from the following companies: Teva pharmaceuticals, KaroBio, J&J, Salix Pharmaceuticals, and Gilead Sciences and has received research support from Eli Lilly for research on drug-induced liver disease. Dr. Fontana is on the Speaker‘s Bureau of Genentech and Gilead Sciences and has received research support or consulting fees from Bristol-Myers Squibb, GlaxoSmithKline and Medtronic. Drs. Davern, Hayashi, Kleiner, Engle, Nguyen, Emerson, Purcell, Gu, Serrano and Hoofnagle have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1. Liver injury initially attributed to nevirapine (Case #2) and later considered probably due to chronic HEV infection
a. The portal area is expanded by a chronic inflammatory infiltrate with interface hepatitis indicative of chronic hepatitis. Several eosinophils are present (H&E, 400x). b. There is portal fibrotic expansion with early bridging fibrosis. Ductular reaction is present at the edges of the portal areas (Masson trichrome, 200x).
Figure 2
Figure 2. Acute liver injury attributed to nevirapine (Case #7) and later considered due to hepatitis E
a. The biopsy shows an acute hepatitis pattern with mild canalicular cholestasis. There portal inflammation with many plasma cells and a few eosinophils and moderate interface hepatitis. The parenchyma shows and numerous foci of lobular inflammation with acidophil bodies (H&E, 200x). b. There is early periportal fibrosis and mild ductular reaction (Masson trichrome, 200x).

References

    1. Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology. 2006;43:618–31. - PubMed
    1. Fontana RJ, Seeff LB, Andrade RJ, Björnsson E, Day CP, Serrano J, Hoofnagle JH. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology. 2010;52:730–42. - PMC - PubMed
    1. Emerson SU, Purcell RH. Hepatitis E virus. Rev Med Virol. 2003;13:145–54. - PubMed
    1. Schlauder GG, Dawson GJ, Erker JC, et al. The sequence and phylogenetic analysis of a novel hepatitis E virus isolated from a patient with acute hepatitis reported in the United States. J Gen Virol. 1998;79(Pt 3):447–56. - PubMed
    1. Levine DF, Bendall RP, Teo CG. Hepatitis E acquired in the UK. Gut. 2000;47:740. - PMC - PubMed

Publication types

MeSH terms